Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia

Soheil Meshinchi, Derek L. Stirewalt, Todd A. Alonzo, Quangeng Zhang, David A. Sweetser, William G. Woods, Irwin D. Bernstein, Robert J. Arceci, Jerald P. Radich

Research output: Contribution to journalArticle

Abstract

Activating mutations of receptor tyrosine kinases (RTKs) and their downstream affectors are common in acute myeloid leukemia (AML). We performed mutational analysis of FLT3, c-kit, c-fms, vascular endothelial growth factor (VEGF) receptors (Flt-1, KDR [kinase domain receptor]), and ras genes in a group of 91 pediatric patients with AML treated on Children's Cancer Group clinical trial CCG-2891. Forty-six percent of patients had activating mutations of FLT3 (24.5%), c-kit (3%), or ras (21%) genes. Mutation-positive patients had a higher median diagnostic white blood cell (WBC) count (71.5 vs 19.6 × 109/L; P = .005) and lower complete remission rate (55% versus 76%; P= .046) than mutation-negative patients. The Kaplan-Meier estimate of overall survival (OS) for patients with and without an activating mutation was 34% versus 57%, respectively (P = .035). However, within this group, patients with FLT3/ALM (activation loop mutation) had good outcomes (OS, 86%). Exclusion of the FLT3/ALM from analysis decreased the OS for the remaining mutation-positive patients to 26% (P = .003). Ten of the 23 mutation-positive and 11 of the 34 mutation-negative patients received an allogeneic bone marrow transplant (BMT) in first complete remission (CR). In the mutation-positive group, the disease-free survival (DFS) for the allogeneic BMT recipients was 72% versus 23% for the 13 patients who received chemotherapy or autologous BMT (P = .01). DFS for the mutation-free patients with and without allogeneic BM transplantation was 55% and 40%, respectively (P = .38). Activating mutations in the RTK/ras signaling pathway are common in pediatric AML, and their presence may identify a population at higher risk of poor outcome who may benefit from allogeneic BM transplantation.

Original languageEnglish (US)
Pages (from-to)1474-1479
Number of pages6
JournalBlood
Volume102
Issue number4
DOIs
StatePublished - Aug 15 2003

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this

    Meshinchi, S., Stirewalt, D. L., Alonzo, T. A., Zhang, Q., Sweetser, D. A., Woods, W. G., Bernstein, I. D., Arceci, R. J., & Radich, J. P. (2003). Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood, 102(4), 1474-1479. https://doi.org/10.1182/blood-2003-01-0137